Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

E. Havrdová, DL. Arnold, A. Bar-Or, G. Comi, HP. Hartung, L. Kappos, F. Lublin, K. Selmaj, A. Traboulsee, S. Belachew, I. Bennett, R. Buffels, H. Garren, J. Han, L. Julian, J. Napieralski, SL. Hauser, G. Giovannoni,

. 2018 ; 4 (1) : 2055217318760642. [pub] 20180312

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18009910

Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. Methods: NEDA was assessed in a modified intent-to-treat population (n = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg). Results: NEDA was increased with ocrelizumab vs IFN β-1a over 96 weeks by 75% (p < 0.001), from Week 0‒24 by 33% (p < 0.001) and from Week 24‒96 by 72% (p < 0.001). Among patients with disease activity during Weeks 0‒24, 66.4% vs 24.3% achieved NEDA during Weeks 24‒96 in the ocrelizumab and IFN β-1a groups (relative increase: 177%;p < 0.001). Conclusion: Superior efficacy with ocrelizumab compared with IFN β-1a was consistently seen in maintaining NEDA status in all epochs evaluated. By contrast with IFN β-1a, the majority of patients with disease activity early in the study subsequently attained NEDA status with ocrelizumab.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18009910
003      
CZ-PrNML
005      
20210510122453.0
007      
ta
008      
180404s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2055217318760642 $2 doi
035    __
$a (PubMed)29568544
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Havrdová, Eva $u Department of Neurology and Center for Clinical Neuroscience, Charles University, Czech Republic.
245    10
$a No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a / $c E. Havrdová, DL. Arnold, A. Bar-Or, G. Comi, HP. Hartung, L. Kappos, F. Lublin, K. Selmaj, A. Traboulsee, S. Belachew, I. Bennett, R. Buffels, H. Garren, J. Han, L. Julian, J. Napieralski, SL. Hauser, G. Giovannoni,
520    9_
$a Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. Methods: NEDA was assessed in a modified intent-to-treat population (n = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg). Results: NEDA was increased with ocrelizumab vs IFN β-1a over 96 weeks by 75% (p < 0.001), from Week 0‒24 by 33% (p < 0.001) and from Week 24‒96 by 72% (p < 0.001). Among patients with disease activity during Weeks 0‒24, 66.4% vs 24.3% achieved NEDA during Weeks 24‒96 in the ocrelizumab and IFN β-1a groups (relative increase: 177%;p < 0.001). Conclusion: Superior efficacy with ocrelizumab compared with IFN β-1a was consistently seen in maintaining NEDA status in all epochs evaluated. By contrast with IFN β-1a, the majority of patients with disease activity early in the study subsequently attained NEDA status with ocrelizumab.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arnold, Douglas L $u Department of Neurology and Neurosurgery, McGill University, Canada. NeuroRx Research, Canada.
700    1_
$a Bar-Or, Amit $u Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania, USA.
700    1_
$a Comi, Giancarlo $u Neurology Department and INSPE-Institute of Experimental Neurology, Vita-Salute San Raffaele University, Italy.
700    1_
$a Hartung, Hans-Peter $u Medical Faculty, Heinrich Heine University Düsseldorf, Germany.
700    1_
$a Kappos, Ludwig $u Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, Switzerland.
700    1_
$a Lublin, Fred $u Department of Neurology, Icahn School of Medicine at Mount Sinai, USA.
700    1_
$a Selmaj, Krzysztof $u Medical University of Lodz, Poland.
700    1_
$a Traboulsee, Anthony $u Division of Neurology, Department of Medicine, University of British Columbia, Canada. $7 xx0260377
700    1_
$a Belachew, Shibeshih $u F. Hoffmann-La Roche Ltd, Switzerland.
700    1_
$a Bennett, Iain $u F. Hoffmann-La Roche Ltd, Switzerland.
700    1_
$a Buffels, Regine $u F. Hoffmann-La Roche Ltd, Switzerland.
700    1_
$a Garren, Hideki $u Genentech Inc, USA.
700    1_
$a Han, Jian $u Genentech Inc, USA.
700    1_
$a Julian, Laura $u Genentech Inc, USA.
700    1_
$a Napieralski, Julie $u F. Hoffmann-La Roche Ltd, Switzerland.
700    1_
$a Hauser, Stephen L $u Department of Neurology University of California, San Francisco, USA.
700    1_
$a Giovannoni, Gavin $u Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, UK.
773    0_
$w MED00194908 $t Multiple sclerosis journal - experimental, translational and clinical $x 2055-2173 $g Roč. 4, č. 1 (2018), s. 2055217318760642
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29568544 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20210510122453 $b ABA008
999    __
$a ind $b bmc $g 1287395 $s 1006722
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 4 $c 1 $d 2055217318760642 $e 20180312 $i 2055-2173 $m Multiple sclerosis journal - experimental, translational and clinical $n Mult Scler J Exp Transl Clin $x MED00194908
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace